glp-1 news october 16 2025 RA Weight Loss Drugs May Carry Untold Ocular Burden GLP-1 Drugs: 2025 Pulse Survey

When comparing GHK-Cu vs AHK-Cu for hair growth appearance, GHK-Cu has the larger body of clinical research supporting it, while AHK-Cu offers a hair-focused alternative with emerging research

Sleep quality affects GLP-1 sensitivity Poor sleep directly impairs GLP-1 sensitivity and secretion

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained

Levothyroxine: a medicine for an underactive thyroid (hypothyroidism) NHS

Peer review Peer review information Nature Communications thanks Cristina Al-Khalili Szigyarto and the other, anonymous, reviewers for their contribution to the peer review of this work